IL299142A - Methods for detecting and predicting cancer and/or cin3 - Google Patents
Methods for detecting and predicting cancer and/or cin3Info
- Publication number
- IL299142A IL299142A IL299142A IL29914222A IL299142A IL 299142 A IL299142 A IL 299142A IL 299142 A IL299142 A IL 299142A IL 29914222 A IL29914222 A IL 29914222A IL 299142 A IL299142 A IL 299142A
- Authority
- IL
- Israel
- Prior art keywords
- cpgs
- cancer
- assay
- panel
- identified
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 111
- 201000011510 cancer Diseases 0.000 title claims description 110
- 238000000034 method Methods 0.000 title description 13
- 238000003745 diagnosis Methods 0.000 title description 2
- 101150070189 CIN3 gene Proteins 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 238000003556 assay Methods 0.000 claims description 76
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 28
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 28
- 230000011987 methylation Effects 0.000 claims description 26
- 238000007069 methylation reaction Methods 0.000 claims description 26
- 238000011161 development Methods 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000013178 mathematical model Methods 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 description 25
- 206010014733 Endometrial cancer Diseases 0.000 description 22
- 230000002357 endometrial effect Effects 0.000 description 18
- 206010033128 Ovarian cancer Diseases 0.000 description 14
- 206010061535 Ovarian neoplasm Diseases 0.000 description 14
- 230000002611 ovarian Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 8
- 238000009595 pap smear Methods 0.000 description 7
- 230000007067 DNA methylation Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2009224.3A GB202009224D0 (en) | 2020-06-17 | 2020-06-17 | Methods for detecting and predicting cancer and/or cin3 |
| GBGB2107412.5A GB202107412D0 (en) | 2021-05-25 | 2021-05-25 | Methods for detecting and predicting cancer and/or CIN3 |
| PCT/GB2021/051536 WO2021255459A1 (en) | 2020-06-17 | 2021-06-17 | Methods for detecting and predicting cancer and/or cin3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299142A true IL299142A (en) | 2023-02-01 |
Family
ID=76730905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299142A IL299142A (en) | 2020-06-17 | 2021-06-17 | Methods for detecting and predicting cancer and/or cin3 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240191302A1 (https=) |
| EP (1) | EP4168587A1 (https=) |
| JP (1) | JP2023530983A (https=) |
| KR (1) | KR20230024344A (https=) |
| AU (1) | AU2021291133A1 (https=) |
| BR (1) | BR112022025789A2 (https=) |
| CA (1) | CA3186997A1 (https=) |
| IL (1) | IL299142A (https=) |
| MX (1) | MX2022016100A (https=) |
| WO (1) | WO2021255459A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202315787D0 (en) * | 2023-10-16 | 2023-11-29 | Sola Diagnostics Gmbh | Method |
| GB202401477D0 (en) * | 2024-02-05 | 2024-03-20 | Sola Diagnostics Gmbh | Method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033627A2 (en) * | 2011-09-01 | 2013-03-07 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| WO2016041010A1 (en) * | 2014-09-15 | 2016-03-24 | Garvan Institute Of Medical Research | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor |
| US9984201B2 (en) * | 2015-01-18 | 2018-05-29 | Youhealth Biotech, Limited | Method and system for determining cancer status |
| JP7299158B2 (ja) * | 2017-03-10 | 2023-06-27 | セルフ－スクリーン ベー．フェー． | Ｈｐｖ誘発浸潤がん、非ｈｐｖ誘発婦人科がん及び肛門性器がん、並びにその高度前駆病変を検出するためのメチル化分類子 |
| US12480164B2 (en) * | 2018-12-04 | 2025-11-25 | EpiMedTechGlobal (EMTG) | DNA methylation biomarkers for early detection of cervical cancer |
-
2021
- 2021-06-17 US US18/009,945 patent/US20240191302A1/en active Pending
- 2021-06-17 AU AU2021291133A patent/AU2021291133A1/en active Pending
- 2021-06-17 JP JP2022577444A patent/JP2023530983A/ja active Pending
- 2021-06-17 KR KR1020237000635A patent/KR20230024344A/ko active Pending
- 2021-06-17 WO PCT/GB2021/051536 patent/WO2021255459A1/en not_active Ceased
- 2021-06-17 BR BR112022025789A patent/BR112022025789A2/pt unknown
- 2021-06-17 EP EP21736665.7A patent/EP4168587A1/en active Pending
- 2021-06-17 MX MX2022016100A patent/MX2022016100A/es unknown
- 2021-06-17 CA CA3186997A patent/CA3186997A1/en active Pending
- 2021-06-17 IL IL299142A patent/IL299142A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022016100A (es) | 2023-04-20 |
| CA3186997A1 (en) | 2021-12-23 |
| BR112022025789A2 (pt) | 2023-01-10 |
| WO2021255459A1 (en) | 2021-12-23 |
| JP2023530983A (ja) | 2023-07-20 |
| AU2021291133A1 (en) | 2023-02-02 |
| KR20230024344A (ko) | 2023-02-20 |
| EP4168587A1 (en) | 2023-04-26 |
| US20240191302A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI912702B (zh) | 異常片段偵測及分類 | |
| Urban et al. | Ovarian cancer screening | |
| CN111863250B (zh) | 一种早期乳腺癌的联合诊断模型及系统 | |
| Ribal et al. | Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study | |
| KR20200035427A (ko) | 세포-무함유 바이러스 핵산을 사용하는 암 스크리닝의 증강 | |
| US11585816B2 (en) | Automated method for assessing cancer risk using tissue samples, and system therefor | |
| Uijterwaal et al. | Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN | |
| CN111440869A (zh) | 一种用于预测原发性乳腺癌发生风险的dna甲基化标记物及其筛选方法和应用 | |
| IL299142A (en) | Methods for detecting and predicting cancer and/or cin3 | |
| Rozemeijer et al. | Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer | |
| de Jong et al. | A urine-based genomic assay improves risk stratification for patients with high-risk hematuria stratified according to the American Urological Association guidelines | |
| CA3198479A1 (en) | Panel of mirna biomarkers for diagnosis of ovarian cancer, method for in vitro diagnosis of ovarian cancer, uses of panel of mirna biomarkers for in vitro diagnosis of ovarian cancer and test for in vitro diagnosis of ovarian cancer | |
| IL299143A (en) | Methods for detecting and predicting grade 3 cervical epithelial neoplasia (cin3) and/or cancer | |
| CN109715828B (zh) | 用于子宫内膜异位症检测的生物标志物组合及其应用 | |
| US20200318190A1 (en) | Stratification of risk of virus associated cancers | |
| Calcatera et al. | Concordance of pre-operative clinical stage with pathologic stage in patients≥ 45 years old with well-differentiated thyroid cancer | |
| Dai et al. | Development of an approach for ab initio estimation of compound-induced liver injury based on global gene transcriptional profiles | |
| TWI886817B (zh) | 甲基化生物標記用於篩檢泌尿道上皮癌的方法 | |
| WO2018049946A1 (zh) | 用于子宫腺肌症检测的生物标志物组合及其应用 | |
| US20240117444A1 (en) | Biomarkers for the diagnosis of breast cancer | |
| Hu et al. | Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification | |
| Huang et al. | Prognostic nomogram for predicting the overall survival rate of patients with uterine clear‐cell carcinoma: Based on SEER database | |
| US20230408522A1 (en) | Multi-protein classifier for detecting early-stage ovarian cancer | |
| Van Laar et al. | Translation of a Circulating microRNA Signature of Melanoma to a Novel Solid-Tissue Biomarker to Improve Diagnostic Accuracy and Reproducibility. | |
| CN116445614A (zh) | 用于检测宫颈鳞癌的核酸分子、试剂盒及其应用 |